Translation. Region: Russian Federation –
Source: People's Republic of China in Russian – People's Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Source: People's Republic of China – State Council News
BEIJING, Dec. 2 (Xinhua) — China on Tuesday launched a drug price registration system, providing global pharmaceutical companies with online and offline price registration and identification services.
This means that Chinese pharmaceutical companies will have a “price pass” when going global, as the https://chinamedreg.com.cn platform offers authoritative, standardized and transparent market price registration and identification services that are recognized worldwide.
According to the National Medical Security Administration of China, pharmaceutical companies can independently submit price registration applications based on their needs and are responsible for their authenticity. The system operator will not interfere with price determination during the processing of applications.
After this, the holder of the license allowing the drug to enter the market can receive a multilingual certificate of registered price identification, which certifies the registration of the price.
Observers note that the system is expected to help address the problem of insufficient access to price monitoring in the Chinese market, which is typical for new Chinese drugs entering international markets.
Observers say this will also facilitate the early entry of more innovative drugs with global competitiveness into the Chinese market.
To date, price registration has been completed for the first batch of drugs from nine pharmaceutical companies from China and foreign countries, including the Swiss company Roche. –0–
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.